Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan by Mohammad Faizan Zahid, Natasha Ali, Myra Nasir, Maria Haider Baig, Mustafa Iftikhar, Syed Usman Bin Mahmood, Arhama Malik, Sara Atif, Mohammad Asim Beg

“…In 160 (65.5%) episodes, the organism was not isolated. Thalidomide with dexamethasone was the most common treatment regimen, followed by melphalan with dexamethasone. …”
Get full text

Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient by Pedro Ventura Aguiar, Carla Dias, Pedro Azevedo, Hugo Neves Silva, Manuela Almeida, Sofia Pedroso, La Salete Martins, Leonídio Dias, Anabela Rodrigues, Ramón Viscaíño, António Cabrita, António Castro Henriques

“…In spite of having started treatment with etoposide and thalidomide, no clinical response was achieved and the patient died three months later. …”
Get full text

TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation by Belarbi Karim, Jopson Timothy, Tweedie David, Arellano Carla, Luo Weiming, Greig Nigel H, Rosi Susanna

“…Our study was aimed to evaluate the therapeutic potential of a novel analog of thalidomide, 3,6'-dithiothalidomide (DT), an agent with anti-TNF-α activity, in a model of chronic neuroinflammation.…”
Get full text

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma by T. A. Мitinа, A. K. Golenkov, E. V. Trifonova, E. V. Kataeva, L. L. Vysotskaya, Yu. B. Chernykh, S. G. Zakharov, K. A. Belousov, A. V. Karaulov

“…The prior therapy for all patients included bortezomib-based treatment in combination with thalidomide and autologus stem cell transplantation (8.1 %). …”
Get full text

Alterations in choroidal vascular structures due to serum levels of vascular endothelial growth factor in patients with POEMS syndrome by Hirotaka Yokouchi, Daisuke Nagasato, Yoshinori Mitamura, Mariko Egawa, Hitoshi Tabuchi, Sonoko Misawa, Satoshi Kuwabara, Takayuki Baba

“…Enhanced depth imaging optical coherence tomography (EDI-OCT) images were obtained, and serum VEGF levels were measured at baseline and 6 months after transplantation with dexamethasone (n = 6), thalidomide (n = 8), or lenalidomide (n = 3). EDI-OCT images were binarized using ImageJ software, and we calculated the areas of the whole choroid and the luminal and stromal areas. …”
Get full text

Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia by Carmine Liberatore, Francesca Fioritoni, Annalisa Natale, Guido Montanaro, Gaetano La Barba, Cecilia Passeri, Ornella Iuliani, Bianca Fabi, Stefano Baldoni, Donatella Fantasia, Giuseppe Calabrese, Patrizia Accorsi, Stella Santarone, Stefano Pulini, Mauro Di Ianni

“…We report on the first patient diagnosed with CML and MM treated with daratumumab, bortezomib, thalidomide, and dexamethasone (Dara‐VTd) induction, stem‐cell collection, and autologous stem cell transplantation (ASCT). …”
Get full text

Successful outcome in a case of idiopathic multicentric Castleman disease with atypical lymphadenopathy and kidney injury: Diagnostic challenges and treatment approach—Case report... by Dilina Yalikun, Jing Zhuang, Wei Lei, Chun Wang, Ailima Aierken, Yue Qu, Junyan Wang, Xuefei Tian, Hong Jiang

“…Treatment includes thalidomide, cyclophosphamide, and dexamethasone, as well as supportive measures and infection control. …”
Get full text

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results by Holger W. Auner, Sarah R. Brown, Katrina Walker, Jessica Kendall, Bryony Dawkins, David Meads, Gareth J. Morgan, Martin F. Kaiser, Mark Cook, Sadie Roberts, Christopher Parrish, Gordon Cook

“…We carried out MUKeight, a randomised, controlled, open, parallel group, multi-centre phase II trial in patients with relapsed MM after prior treatment with thalidomide, lenalidomide, and a proteasome inhibitor (ISRCTN58227268), with the primary objective to test whether ICD has improved clinical activity compared to cyclophosphamide and dexamethasone (CD) in terms of progression-free survival (PFS). …”
Get full text

The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis by Xiaohua Huang, Yuan Liu, Ruixuan Liu, Xiaoqiu Zou, Hongyong Yang

“…ATO + Traditional Chinese Medicine (TCM), ATO + Thalidomide (T)+TCM, ATO + Chemotherapy (Chem)+T + TCM were regarded as the optimal combination, which improved both ORR, CR and HI in theory. …”
Get full text

Telangiectasia hemorrágica hereditária: resposta hematológica após terapêutica com talidomida by Eduardo Ribeiro, Eduardo Oliveira, Isabel Bastos, Carlos Seabra

“…Here we describe a dramatic improvement of a patient with HHT and severe iron deficiency anemia, requiring frequent blood transfusion, successfully treated with thalidomide, without side effects.…”
Get full text

Clinical Features of Paediatric Inflammatory Epidermolysis Bullosa Acquisita: A Case Series Study by Yuexin Zhang, Jingyang Dang, Ruoyu Li, Xixue Chen, Xuejun Zhu, Mingyue Wang

“…In addition to treatment with glucocorticoids, dapsone was administered in 4 patients, while thalidomide and sulfasalazine were administered in 1 patient. …”
Get full text

Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients by Fang Fang, Xiao-Xi Lan, Rong-Hua Hu, Wu-Han Hui, Hong Zhao, Yi-Xian Guo, Bing-Xin Ji, Hong-Jun Liu, Li Su, Wan-Ling Sun

“…Second, to compare the efficacy and safety of regimens with a proteasome inhibitor (bortezomib–cyclophosphamide–dexamethasone, BCD) or without a proteasome inhibitor (cyclophosphamide–dexamethasone ± thalidomide, CD ± T). Design: We conducted a retrospective study using real-world data from Capital Medical University, Xuanwu Hospital. …”
Get full text

Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting by Antonio G. Solimando, Markus Krebs, Vanessa Desantis, Donatello Marziliano, Ingrid Catalina Caradonna, Arcangelo Morizio, Antonella Argentiero, Endrit Shahini, Max Bittrich

“…These advancements include thalidomide and its derivatives, lenalidomide and pomalidomide, which exhibit diverse mechanisms of action against the plasma cell clone. …”
Get full text

First use of 18F-FDG PET in TEMPI syndrome: can it be used for treatment assessment? A case report by Henri Pasquesoone, Aurélien Callaud, Thibaut Carsuzaa, Thomas Chalopin, Maria-Joao Santiago-Ribeiro, Maria-Joao Santiago-Ribeiro

“…Post-treatment 18F-FDG PET (Daratumumab Bortezomib Thalidomide Dexamethasone) revealed a completely reduced signal of bone lesions, suggesting a complete response, which was substantiated both clinically and biologically, with the concurrent disappearance of telangiectasia and the monoclonal component, and the normalization of the EPO level. …”
Get full text

IL-10/β-Endorphin-Mediated Neuroimmune Modulation on Microglia during Antinociception by Thiago Caetano Andrade Belo, Gabriela Xavier Santos, Bruno Eduardo Gabriel da Silva, Bruno Lopes Gonçalves Rocha, Dennis William Abdala, Larissa Alves Moreira Freire, Fernanda Santos Rocha, Giovane Galdino

“…In addition, molecules such as gabapentinoids, thalidomide, cynandione A, morroniside, lemairamin, and cinobufagin, as well as non-pharmacological treatments such as electroacupuncture, reduce pain through IL-10 mediated mechanisms, reflecting a microglia-dependent β-endorphin differential increase. …”
Get full text

Beta-Thalassemia: A Pharmacological Drug-Based Treatment by Shrabonti Biswas, Shanita Zaman Smrity, Md. Shimul Bhuia, Fatema Akter Sonia, Mst. Asma Aktar, Raihan Chowdhury, Tawhida Islam, Muhammad Torequl Islam, Gabriel Gonçalves Alencar, Cicera Laura Roque Paulo, Ana Pavla Almeida Diniz Gurgel, Henrique Douglas Melo Coutinho

“…According to this review, clinical trials for a number of drugs, including luspatercept, sotatercept, mitapivat, etavopivat, hydroxyurea, rapamycin, decitabine, thalidomide, and quercetin, have been performed as part of efforts to improve the cure strategy for β-thalassemia. …”
Get full text

First Line Systemic Treatment for MALT Lymphoma—Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna by Barbara Kiesewetter, Ingrid Simonitsch-Klupp, Marius E. Mayerhoefer, Werner Dolak, Julius Lukas, Markus Raderer

“…Regarding the type of first line treatment and outcome, 46% (74/159) received a chemotherapy-based regimen and 54% (85/159) immunotherapy including IMiDs lenalidomide/thalidomide (37%), anti-CD20-anitbodies rituximab/ofatumumab (27%), macrolides clarithromycin/azithromycin (27%) and proteasome inhibitor bortezomib (9%). …”
Get full text

Evaluation of cytokines as diagnostic and therapeutic indicators for recurrent aphthous stomatitis: A statistical study by Xuan Xiao, Yiwen Deng, Yuanyuan Long, Wei Liu, Huan Shi

“…The effect of levamisole and thalidomide on cytokines mainly were IL-6, TNF-α, and IL-8. …”
Get full text

Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review by Aneta Szudy-Szczyrek, Sylwia Chocholska, Oliwia Bachanek-Mitura, Olga Czabak, Radosław Mlak, Michał Szczyrek, Justyna Muzyka-Kasietczuk, Marek Hus

“…Previous chemotherapy regimens included thalidomide and bortezomib. Median duration of exposure to ixazomib was 12 months. …”
Get full text

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation by Satoshi Yamanaka, Hirotake Furihata, Yuta Yanagihara, Akihito Taya, Takato Nagasaka, Mai Usui, Koya Nagaoka, Yuki Shoya, Kohei Nishino, Shuhei Yoshida, Hidetaka Kosako, Masaru Tanokura, Takuya Miyakawa, Yuuki Imai, Norio Shibata, Tatsuya Sawasaki

“…Thus, 6-position-modified lenalidomide is a key molecule for selective TPD using thalidomide derivatives and PROTACs.…”
Get full text